Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice.

Psoriasis (Auckl) · 2025 · PMC11956732 · PMID 40166484

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

5 , 23 , 34 This factor was only of borderline significance in our analysis.

also in 2,624 other papers

showed a trendno p-value reported

Ixekizumab showed a trend toward faster and higher Psoriasis Area and Severity Index (PASI) 75 and 90 response rates compared to secukinumab at weeks 52 (74.6% versus 55.4%) and 104 (41.5% versus 31.1%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.